Amgen (AMGN)

• Market cap: $163B
• 1 day: 1.71%
• 5 days: 2.80%
• 1 month: 10.26%
• 3 months: 4.52%
• 6 months: -7.94%
• Year to date: 16.87%
• 1 year: 6.90%
• 5 years: 36.01%
• 10 years: 91.27%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Employees: 26,700

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

9% more call options, than puts

Call options by funds: $1.98B | Put options by funds: $1.81B

8% more first-time investments, than exits

New positions opened: 249 | Existing positions closed: 231

0.76% more ownership

Funds ownership: 76.39% [Q3] → 77.15% (+0.76%) [Q4]

5% less repeat investments, than reductions

Existing positions increased: 1,022 | Existing positions reduced: 1,080

4% less funds holding

Funds holding: 2,782 [Q3] → 2,666 (-116) [Q4]

15% less capital invested

Capital invested by funds: $132B [Q3] → $111B (-$20.3B) [Q4]

48% less funds holding in top 10

Funds holding in top 10: 69 [Q3] → 36 (-33) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $275 9% downside
• Avg. target: $300 1% downside
• High target: $329 9% upside

6 analyst ratings

• positive: 2 33%
• neutral: 3 50%
• negative: 1 17%

Piper Sandler David Amsellem 63% 1-year accuracy 22 / 35 met price target	9% upside $329	Overweight Maintained	10 Feb 2025
B of A Securities Tim Anderson 56% 1-year accuracy 5 / 9 met price target	9% downside $275	Underperform Maintained	6 Feb 2025
Citigroup Geoff Meacham 50% 1-year accuracy 15 / 30 met price target	3% downside $295	Neutral Maintained	28 Jan 2025
RBC Capital Gregory Renza 30% 1-year accuracy 25 / 83 met price target	7% upside $324	Outperform Reiterated	24 Jan 2025
Wells Fargo Mohit Bansal 44% 1-year accuracy 11 / 25 met price target	8% downside $280	Equal-Weight Maintained	10 Jan 2025